Your browser doesn't support javascript.
loading
Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies.
Yang, Renchi; Zhao, Yongqiang; Wang, Xuefeng; Sun, Jing; Wu, Runhui; Jin, Chenghao; Jin, Jie; Wu, Depei; Rendo, Pablo; Sun, Feifei; Rupon, Jeremy; Huard, Francois; Korth-Bradley, Joan M; Xu, Lihong; Luo, Binyu; Liu, Yingxue Cathy.
Affiliation
  • Yang R; Thrombosis and Hemostasis Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
  • Zhao Y; Department of Hematology, Peking Union Medical College Hospital, Beijing, People's Republic of China.
  • Wang X; Department of Clinical Blood Transfusion, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Sun J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
  • Wu R; Department of Hematology, Beijing Children's Hospital and Capital Medical University, Beijing, People's Republic of China.
  • Jin C; Department of Hematology, Jiangxi Provincial People's Hospital, Jiangxi, People's Republic of China.
  • Jin J; Department of Hematology, The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Wu D; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
  • Rendo P; Rare Disease, Pfizer Inc, Collegeville, PA, USA.
  • Sun F; Pfizer (China) Research & Development Co, Ltd, Shanghai, People's Republic of China.
  • Rupon J; Rare Disease, Pfizer Inc, Collegeville, PA, USA.
  • Huard F; Clinical Pharmacology, Pfizer PIO, Paris, France.
  • Korth-Bradley JM; Pfizer Inc, Collegeville, PA, USA.
  • Xu L; Pfizer (China) Research & Development Co, Ltd, Shanghai, People's Republic of China.
  • Luo B; Pfizer (China) Research & Development Co, Ltd, Shanghai, People's Republic of China.
  • Liu YC; Statistics, Pfizer (China) Research & Development Co, Ltd, Shanghai, People's Republic of China.
J Blood Med ; 11: 439-448, 2020.
Article in En | MEDLINE | ID: mdl-33269010
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: J Blood Med Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: J Blood Med Year: 2020 Type: Article